Total pharma industry private equity deals in Q2 2019 worth $2.98bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 66.5% over the previous quarter and a drop of 6.9% when compared with the last four-quarter average, which stood at $3.21bn.
Comparing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $1.56bn. At the country level, Italy topped the list in terms of deal value at $1.47bn.
In terms of volumes, North America emerged as the top region for pharma industry private equity deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of private equity deals activity in Q2 2019 was the US with 13 deals, followed by the UK with three and Italy with three.
In 2019, as of the end of Q2 2019, pharma private equity deals worth $4.62bn were announced globally, marking a decrease of 46.03% year on year.
Pharma industry private equity deals in Q2 2019: Top deals
The top five pharma industry private equity deals accounted for 85.7% of the overall value during Q2 2019.
The combined value of the top five pharma industry private equity deals stood at $2.56bn, against the overall value of $2.98bn recorded for the quarter. The top announced pharma industry private equity deal tracked by GlobalData in Q2 2019 was Intermediate Capital Group and Merieux Equity Partners’ $1.24bn private equity deal with DOC Generici.
In second place was the $650m private equity deal with Catalent by Leonard Green & Partners and in third place was Alto Capital IV Fund’s $236.63m private equity deal with OFI Officina Farmaceutica Italiana.
The $235m private equity deal with Asklepios BioPharmaceutical by TPG Capital Management and Vida Ventures and Oberland Capital Management’s private equity deal with Esperion Therapeutics for $200m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.